within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BX04_Romiplostim;

model Romiplostim
  extends Pharmacolibrary.Drugs.ATC.B.B02BX04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B02BX04</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Romiplostim is a thrombopoietin receptor agonist (TPO-RA) that stimulates platelet production by binding to and activating the thrombopoietin receptor (c-Mpl). It is approved for the treatment of chronic immune (idiopathic) thrombocytopenia purpura (ITP) in adult patients who are refractory to other treatments such as corticosteroids, immunoglobulins, or splenectomy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with chronic ITP, as described in clinical trials and modeling reports. Typically, a two-compartment model with subcutaneous administration is used. Parameters reflect mean estimates across adult patient populations.</p><h4>References</h4><ol><li><p>Frampton, JE, &amp; Lyseng-Williamson, KA (2009). Romiplostim. <i>Drugs</i> 69(3) 307–317. DOI:<a href=\"https://doi.org/10.2165/00003495-200969030-00006\">10.2165/00003495-200969030-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19275274/\">https://pubmed.ncbi.nlm.nih.gov/19275274</a></p></li><li><p>Makarenko, I, et al., &amp; Drai, R (2023). A randomized, double-blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers. <i>Pharmacology research &amp; perspectives</i> 11(5) e01125–None. DOI:<a href=\"https://doi.org/10.1002/prp2.1125\">10.1002/prp2.1125</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37740581/\">https://pubmed.ncbi.nlm.nih.gov/37740581</a></p></li><li><p>Perreault, S, &amp; Burzynski, J (2009). Romiplostim: a novel thrombopoiesis-stimulating agent. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 66(9) 817–824. DOI:<a href=\"https://doi.org/10.2146/ajhp080524\">10.2146/ajhp080524</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19386944/\">https://pubmed.ncbi.nlm.nih.gov/19386944</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Romiplostim;
